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studied enzymes such as Factor IX and XI . Thiol esters may also be useful as su 
strates for enzymes such as Factor
a
  XIIa were the complete sequence at the Factor 
XII cleavage site in Factor XI is not yet known. The second major aspect of our re- 
search involves synthesis and study of peptides with the sequences corresponding to 
plasma protease cleavage sites. We intend to measure their binding to various enzymes, 
their rates of cleavage and compare their reactivity with the reactivity of the natural 
substrates. 
This project has been underway for 1 3/4 years starting on 
August I, 1978. 
Two predoctoral graduate research assistants have worked on the project. Brian 
McRae began work in April, 1979 on the synthesis of peptide thiol esters. Mario 
Castillo began work in February, 1979 on the synthesis of peptides with cleavage site 
sequences. Both have worked continuously on the project since that time. Full time 
graduate research assistants are listed at 40% time. I also received one month's 
salary (8.25% time) from the grant in the summers of 1979 and 1980. 
The specific aims of the previous project were essentially identical with those of 
the current proposal and are stated above in Section A. 
No publications have yet resulted from this research. One manuscript entitled 
"Mapping the Active Sites of Bovine Factor IX, Factor X, Factor XI, Thrombin and 






, K. Kurachi, 
Earl Davie and James C. Powers is in the stage of a first draft. I stopped work on 
that manuscript in order to complete this proposal before the June 1st deadline. I 
expect to submit the manuscript to Biochemistry in midsummer. 
Amino Acid and. Peptide Thiol Esters. One problem-encountered with many of the 
synthetic substrates which have been studied with plasma serine proteases is the low 
sensitivity of the substrate which require the use of large amounts of enzyme for the 
assays. Amino acid and peptide thiol esters have been utilized recently in the devel-
opment of sensitive assays for chymotrypsin (Farmer and Hageman, 1975), elastase 
(Castillo et. al., 1979), and trypsin (Green and Shaw, 1979). Cleavage of the thiol 
ester bond by the enzyme yields a thiol which is continuously determined spectro-
photometrically by measuring the release of a chromogenic product upon reaction with a 
thiol reagent such as 2,2-dithiodipyridine contained in the assay mixture. 
Thiol esters are good substrates for serine proteases and since thiol reagent can 
detect low levels of thiols, the substrates are quite sensitive. In a recent study of 
the merits of various chromophoric and fluorogenic leaving groups (Castillo et. al., 
1979), we showed that an elastase assay using Mee-Suc-Ala-Ala-Pro-Val-SCH 2C0.5 was more 
sensitive than those using either the 4-nitroanilide or the aminomethylcoumarin 
leaving group. The above substrate could be used to detect human leukocyte elastase 
concentrations as low as 5 picomolar. 
We have now shown that peptide thiol esters of the same type can be used in sen-
sitive assays for the serine proteases of the coagulation and complement systems. 
RCO-Arg-SR 4- RCO-Arg-OH + RSH 
The synthesis of a series of amino acid and peptide thiol esters has now been complete 
and three of the simple derivatives are shown below. CH CH CH(CH
3
)
2 2 3 




Boc-Arg-S-CH2 	 Boc-Arg-S-CH2 Boc-S-bi2 
Boc-Arg-SBu-i 	 Boc-Arg-SPe-i 	Boc-Arg-SPe-s 
The structures incorporate respectively the side chains of a P; valine, leucine and 
isoleucine residue. The activation sites of the zymogens of all known serine proteases 
involve cleavage of a Arg-Val, Arg-Leu, or Arg-Ile bond. These three substrates have 
allowed us to study the P 1 - specificity of a number of plasma serine proteases. 
The relative k 	/K.m  values for all the substrates are listed in the following cat 
Table. The substrates were studied at pH 7.5, 0.1 M HEPES buffer, 0.01 M CaC1 2 , 98% 
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Boc-Arg-SBu-i 70 50 0.0 1.0 4.7 
Boc-Arg-SPe-i '139 63 0.0 0.87 2.1 
Boc-Arg-SPe-s 50 80 0.0 0.73 2.8 
Boc-Arg-SBz1 87 $3 0.0 2.4 6.7 
Z-Arg-SBu-i 220 31 0.0 2.6 5.7 
Z-Gly-Arg-SBu-i 150 19 0.0 4.3 4.0 
Z-Ala-Arg-SBu-i 93 23 0.0 2.0 3.2 
Z-Val-Arg-SBu-i 130 3.3 0.0 0.67 2.0 
Boc-Met-Arg-SBu-i 80 7.0 0.0 0.40 2.3 
Z-Phe-Arg-SBu-i 220 29 0.37 1.3 4.0 
Z-Trp-Arg-SBu-i 200 1.0 0.70 1.0 3.7 
Boc-Pro-Arg-SBu-i 70 67 0.0 0.24 0.60 
Z-Ser-Arg-SBu-i 160 4.7 0.0 1.1 3.7 
Z-Thr-Arg-SBu-i 210 4.7 0.0 0.37 2.5 
Z-Asn-Arg-SBu-i 150 5.7 0.0 1-.0 5.7 
Z-Glu-Arg-SBu-i 17 0,40 0.0 1.1 4.0 





value for the hydrolysis of Boc-Arg-SBu-i by Bovine Factor X
a 
set at 1.0. 
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Values for all the kinetic constants 
(kcat,  Km and kcat 
 / 
m
K.) are listed in Tables 
in the appendix. 
The kinetic parameters refer to the well established Scheme for serine proteases 
E.S k2 	 3 		E + P
2 
E+ S  Ks 	 E.S- 	k , 	 > 	 > 
1 







equals k2 1 1 /(k2+k 3 ) becomes the rate limiting deacytation rate (Hirohara et. al., 1977). 




 = k/K. Any non-productive binding 
modes would affect both tc.'cat and KM , but would not change k 
any 	
values. 
The P i " side chain appears to have little effect with c 'y 61 the five enzymes 
studied, at least in the case of simple amino acid thiol ester derivatives. The 
kcat% values for the three thiol esters Boc-Arg-SBu-i, Boc-Arg-SPe-i and Boc-Arg-
Sre-s with each of the five enzymes studied were quite similar. 
We next decided to study dipeptide thiol ester with a variety of amino acid re-
sidues at the P 2 site in order to map the S o subsite of various trypsin-like enzymes. 
Eleven different amino acids with varing side characteristics are represented in the 
substrates listed in the table. Changing the P 9 residue caused the k 	/Km values to 
vary over a 168 fold range with thrombin, 18 fold with Factor X and cf6 fold with 
Factor IX. In each case a different P
2 residue was preferred: aPro for thrombin, Gly for Factora  X ; and Asn for Factor XI . In the case of thrombin and Factor X , these 
are the residues at the P 9 position of the natural 'substrates. The factor XI natural 
substrate has a P
2 Ser and the thiol ester with a P 2 Ser is just slightly poder than the one with a P Asn. 
One highligfit of our research to date is the discovery of two good synthetic 
substrates for Factor IX. Both the substrates (Z-Phe-Arg-SBu-i and Z-Trp-Arg-SBu-i) 
have a P 9 aromatic residuae. As far as I know, there are no other good synthetic sub-
strates for Factor IX
a . Interestingly, the kinetics with Factor IXa 
are more compli-
cated than with other enzymes. At present, it appears that the substrates are acti-
vating Factor IX at higher concentrations and we plan to study this phenomemon further. 
We are also collaborating with Dr. T.Y. Lin (Merck, Rahway, New Jersey) in a study 
of_the reactivity of the various thiol esters with the complement proteases Cls and 
Clr. Only poorly hydrolyzed synthetic substrates are available for these enzymes 
(Andrews and Baillie, 1979). Although we have just begun the kinetic studies, it is 
evident that thiol esters are much more sensitive substrates for Cl;. The three single 
amino acid Toi esters listed earlier, have k
cat 
 /K_ values with Cls in the range of 
m 
6.8 x 10' M s . 
The sensitivity of the various assays can be estimated from the k t /Km values and 
our earlier experience with elastase (Castillo et. al., 1979). The bes
c 
 thrombin sub-
strate should be useful for measuring enzyme concentrations in the range of 5 picomolar. 
The corresponding values with Factor X and XI would be 50 pM and with Factor IX, 500 
pM. Unfortunately, the thiol esters are e not specific enough to be used in situations 
where several of the coagulation factors are present. 
In conclusion, we have developed a series of sensitive synthetic peptide thiol 
ester substrates for a number of plasma proteases, including enzymes (Factor IX a , 
XI , Cls ) for which no other good synthetic substrates are available. These have 
allowed us to map the S2 subsite of the various enzymes studied and are potentially 
useful in future studies of the active sites of various plasma proteases. 
Fluorogenic Peptide Substrates. When we began this research, we planned to syn-
thesize simple peptides corresponding to plasma protease cleavage sites and measure 
their hydrolysis rates using either a riinhydrin or fluorescamine method. Subsequently, 
we decided to change our strategy and to use fluorogenic peptides. A fairly new method 
for the assay of proteolytic enzymes involves the use of peptides containing both a 
fluoroscent and fluorescence-quenching group. Hydrolysis of the peptide with resulting 
P 
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separation of the fluorescent and quenching groups results in an increase in fluo-
rescence which can be used to follow the hydrolysis rate. This technique has been 
used in assays for carboxypeptidase (Latt et. al., 1972), trypsin (Carmel et. al., 
1973), leucine aminopeptidase (Carmel et. al., 1977), and the angiotensin converting 
enzyme (Persson and Wilson, 1977). 
We recently synthesized Abz-Ala-Gly-Leu-Ala-Nba (Abz = o-aminobenzoyl; Nba = 
4-nitrobenzylamide) as a substrate for the Pseudomonas  aeruginosa elastase (Nishino 
and Powers, 1980) ; The substrate has a small amount of intrinsic fluorecence, but 
complete hydrolyti.s led to a 6-to 8-fold increase in fluorescence (excitation, 340 
nm; emission, 415 nm). The P. aeruginosa elastase splits the Gly-Leu bond, but 
cleavage at any of the peptide bonds would result in a fluorescence increase. The 
substrate has been used in our laboratory in a very sensitive rate assay for this 
elastase. 
We decided to use this same technique in the study of peptides with sequences at 
plasma protease cleavage sites. Table VII in the appendix lists the 12 fluorogenic 
peptides we have synthesized to date. The sequences chosen initially correspond to 
Factor IXa
, XI
a and XII cleavage sites. Each peptide contains 5-7 amino acid re- 
sidues encompassing re sidues on both sides of the peptide bond cleaved in the natural 
substrate. Since the sequence on the P side of the Factor XII cleavage site is not 
yet known, we simply placed three alanine residues at P 4-P 2 ana synthesized Abz-Ala-
Ala-Ala-Arg-Ile-Val-Gly-Nba to study with Factor XII . 
The conformation of the individual peptides in.aolution determines to what extent 
the fluorescence of the o-aminobenzoyl group (Abz) is quenched and thus how much the 
fluorescence increases upon hydrolysis. We have found that long peptides are not 
necessarily quenched more poorly than the shorter ones. This indicates that many of 
the longer peptides have conformations in solution where the Abz and Nba groups' are 
much closer to each other than if the peptides were in- a fully extended conformation. 
The hydrolysis of only two peptides have thus far been studied. Both were de-
signed as Factor XI substrates. Abz-Lys-Leu-Thr-Arg-Val-Val-Gly-Nba is hydrolyzed 
 by trypsin (Km = 0.867 TM, k 17s-1 , k
Q t 
/K5 = 260,000 NT s -1 ), -  Factor XI (KM = 
a , 0.75 mM, kcat
=0.083 s , k c
catamm 
	
111 M -L-s - A- and Factor IX (k _/Km = 18aM- ls-1 ), 
but not by factor X or thrombin. Abz-Lys-Phe-Ser-Arg-Val-Val-GlYtipa was hydrolyzed _ 
 by trypsin (Km = 0.883 mM, k cat = 29s-1, kcat = 360,000 M s
- 
 ) and Factor IX a 
(k 	/K_ = 73M-1 s ), but not by Factor IX X , or thrombin. The conditions were 
p0b/1 - , m 0.1 M HEPES, 0.01 M CaC1
2 
at 30 ° C. a' a 
At this stage of the investigation only .a few conclusions can be reached. First 
the rates of cleavage of the peptides by Factor XI are extremely slow compared to the 
trypsin cleavage rate. In each case we expect that  Arg-Val bond is the one being 
cleaved, although we have no evidence for that at present. Importantly, the se-
quence appears to determine specificity. Neither peptide was cleaved after 48 hrs 
by thrombin or Factor X , while Factor IXa cleaved the first peptide at only 16% of 
the rate observed with factor XI. 
The interaction of the other
a 
 peptides listed in Table VII with Factors IX , X a , 
XI , thrombin and trypsin will be studied in the next few weeks. The Factor XI a 
 substrate will be studied as soon as Factor XII isis available. 
D. Future Research Plans and Methods 
Peptide Thiol Esters. We plan to carry out kinetic studies with any additional 
trypsin-like enzymes which become available to us. Specifically we will measure 
k tt , Km and k 	/Km values with the thiol ester substrates listed earlier in the 
tagle. The kifigEic work with Cl; should be finished shortly. We expect to obtain 
samples of Factor XII and kallikrein from Dr. Earl Davie in the near future. Since 
we have already synthe
a 
 sized the substrates, such kinetic studies consume relatively 
little time for the information that is obtained about the S
2 
subsite of the various 
enzymes studied. 
Additional synthetic work will be directed specifically toward Factor IX a and 
Factor XIa substrates, since these two enzymes have been poorly studied. In particular 
15 
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we plan to synthesize Z-Phe-Ser-Arg-SBu-i, Z-Glu-Phe-Ser-Arg-SBu-i, and Z-Asp-Glu-Phe-
Ser-Arg-SBu-i as Factor XI a substrates and Z-Val-Val-Arg-SBu-i, Z-Gln-Val-Val-Arg-SBu- 
i and Z-Ser-Gln-Val-Val-Arg-SBu-i as Factor IX substrates. In each case we are ex- 
tending the substrate by one amino acid residue
a
  at a time and are using the sequence 
at the cleavage site in the natural substrate. This will give us some idea as to the 
length of the extended substrate binding site in these two enzymes. 
We also plan to synthesize the thiol esters Z-Ile-Ala-Gly-Arg-SBu-i and Z-Val-
Ile-Ala-Gly-Arg-S3u-i. These peptides have respectively the P 4 -P i and P 5 -P i sequence 
at the reactive site of antithrombin III (Carrell et. al., 190). They might be 
expected to be equally reactive toward a number of coagulation serine proteases 
since antithrombin III inhibits most of these enzymes. We have found that peptides 
containing the sequence at the active site of the plasma inhibitor a l-antitrypsin 
are hydrolyzed effectively by a number of serine proteases such as human leukocyte 
elastase and cathepsin G with quite different substrate specificities. 
The substrate activation phenomenon observed with Factor IX will be studied a 
further. In particular, we will first see if it is affected by added phospholipids 
such as a combination (1:1) of phosphatidylserine-phosphatidylcholine which is re-
quired for formation of a Factor VIII-Factor IX complex (Davie and Hanahan, 1977). 
It will also be interesting to see if phospholipids increase the Factor IX rate of 
thiol ester hydrolysis. We would also like to study the effect of Factor III on the 
rates, but it may be some time before enough pure Factor VIII is available for such 
studies. 
One significant advantage of thiol ester substrates is their use of P - residues. 
Thus it is possible to design a substrate for an enzyme where only the N-terminal se-
quence released upon cleavage of its substrate is known. Thus a substrate such as 
Z-Arg-Slle-Val-Gly-Gly-NH2 (Slle = SCH(C 4H9 )CO- ) could be used to study or detect 
enzymes that activate Factor VII. 
Our work with simple amino acid thiol esters described above indicates that the 
P
1 residue has little effect on hydrolysis rates. However, we would like to study 
a longer substrate before concluding thatP residues can be ignored in designing 
thiol ester substrates for plasma proteases. We have completed the synthesis of 
HSIle-Val-Gly-Gly-NH 9 and intend to couple it with Z-Arg-OH and study the resulting 
Z-Arg-Slle-Val-Gly-Giy-NH 2 . This substrate has the P 1 through P 4 ' sequence at the 
Factor IX cleavage site and may be hydrolyzed by Factor IX. We will also study 
this peptidea  with the other enzymes which are available. 	
a 
 
The thiol ester substrates which we have developed and are developing will be 
usful for many other investigators in their own studies. Dr. Roger Lundblad (U. of 
North Carolina) for example, has already requested one of our Factor IX substrates 
in order to study the binding of heparin to Factor IX a . 
Substrates with Other Leaving Groups. Once an appropriate thiol ester substrate 
for a protease is discovered, it would be useful to investigate corresponding deri-
vatives where the thiol leaving group is replaced by aminomethylcoumarin (a fluo-
rescent leaving group) or by 4-nitroaniline. In our study with elastase (Castillo 
et. al., 1979), we found the aminomethylcoumarins to be almost as sensitive as the 
thiol esters. The 4-nitroanilides in favorable cases were just slightly less sen-
sitive and are very convenient to use. Both the aminomethylcoumarin and the 4-nitro-
anilide are amide substrates and could be used in situations where the thiol esters 
could not. For example, high concentrations of thiols or protein SH groups would 
interfer with the thiol ester assays, butnot with the amide assays. 
At present we are concentrating on Factor IX and XI substrates. Therefore it 
would appear that dipeptides such as Z-Phe-Arg-NA
a 
 or Z-Phe-Arg-AMC (NA = 4-nitro-
anilide; AMC = aminomethylcoumarin) might be worth investigating as these correspond 
in sequence to one of our better dipeptide thiol ester substrates. However, it has 
been reported that Bz-Ser-Gln-Val-Val-Arg-NA is not cleaved by Factor IX a (Suomela 
et. al., 1977). Therefore, we intend to do more mapping studies with longer thiol 
esters before looking at the corresponding nitroanilides or aminomethylcoumarins. 
16 
Fluorogenic Peptide Substrates. Our first priority is to carry out kinetic 
studies with the fluorogenic substrates which we already synthesized (listed in 
Table VII in appendix). These peptides have sequences corresponding to those 
found in Factor IX, Factor XI
a and Factor XII cleavage sites. The kinetic con- stants k
cat and Kt" (equals K with 	will be determined. 
If tne peptides are not hydrolyzed by a particular enzyme, we will then measure 
its binding constant to that particular enzyme to see if it is binding, but not being 
cleaved. For these studies we will use our thiol ester substrates and treat the 
longer fluorogenic substrates as competive inhibitors. The K1 thus measured will 
give a measure of the binding of the peptides to the various enzymes. It is evident 
that our sensitive thiol ester substrates will allow us to study the binding of 
peptides to enzymes such as Factor IX
a , even if none of the simple peptides are hydrolyzed. 
Studies with peptides should show us the length of the extended substrate binding 
region in proteases such as Factor IX and XI. As the peptide length is increased, 
a point should be reached where furthe
a
 r interaction with the enzyme is not possible 
and no change in KS  (or ICI ) occurs. For example, consider the 4 Factor IXa substrates 
listed in Table VII. Each peptide is related to the previous one by having either 
one less or one more amino acid residue. Kinetic studies with this series of com-




3 , P 4 and P 1 ' residues. 
Studies wag peptides should also show just how important the conformation of 
the natural substrate is in determining the specificity of a plasma proteases. 
Specifically we will compare the rate of bond hydrolysis (k ca,) and the binding 
constant (KM) obtained with the longer peptide substrates to the corresponding 
kinetic constants determined with the natural substrate. Many of the rate constants 
for cleavage of the natural substrates have appeared in the literature (Steinberg 
et. al., 1980). We would expect the Km for the synthetic substrate to be higher 
than for the natural substrate and would conclude that the conformation of the 
substrate affected its binding to the protease. However, the situation is not so 
clearcut in the case of k ' One might expect k 	to be similar in both cases, 
but it could be argued the
cat 
 conformation of the na tural substrate might force the 
plasma protease into a more reactive conformation and increase kcat . Experiments 
with synthetic peptides will help to answer such questions. 
When we reach the point when we have obtained the best possible fluorogenic 
peptide substrate for each enzyme under study, it might be appropriate to synthesize 
a peptide with the same sequence, but lacking the Abz and Nba groups. This would 
show whether these two end groups have any effect on the hydrolysis rate. 
The fluorescent peptides may be useful for study of the rates of binding of 
peptides to proteases. Undoubtly the conformation of a fluorogenic peptide will 
be altered upon binding to a particular enzyme. This should be reflected in a 
fluorescence change. For example, if a peptide such as Abz-Lys-Phe-Ser-Arg-Val-
Val-Gly-Nba bound to Factor XI in a fully extended conformation, there should be 
almost no quenching of the fluorescence of Abz group due to the distance separating 
it from the nitrobenzyl quenching group. At low concentrations of substrate, we 
might be able to observe a fluorescence change simply upon binding to the enzyme 
this and could possibly allow us to measure a binding rate. At present, I don't 
know if our fluorescence spectrometer is sensitive enough to make such measurements. 
Significance. The proposed research should lead to a better understanding of 
the nature of the active structures of various plasma proteases. We will obtain 
basic information concerning the interaction of these proteases with their sub-
strates and natural inhibitors, and how their activity is affected by various plasma 
modulators such as phospholipids. The synthetic substrates which will be developed 
in this research should be quite sensitive and should allow assays to be developed 
for plasma components which are impossible currently due to the complex nature of 
clotting assays. This research may lead to new methods of disease diagnosis and 
could lead to new avenues of therapy where various specific activators or inhibitors 
Page 17 
are used to control the activity of the proteases involved in important physio-
logical processes such as 'blood coagulation, fibrinolysis and complement. 
E. Facilities Available. The School of Chemistry at Georgia Institute of 
Technology moved into a new building in 1970. The facility contains ample research 
and office space. The department is well equipped in instrumentation relevant to 
the proposed research, including a high resolution mass spectrometer and several 
nuclear magnetic resonance spectrometers. A cold room is available in the building. 
The laboratories of the principal investigator are well equipped for the syn-
thesis of peptides and the measurement of their reaction with enzymes. The equipment 
includes a Thermovac freeze drying apparatus, pH staat, Beckman model 25 and model 35 
uv-visible spectrometers, a fluorescence spectrometer and chromatographic equipment. 
We have constructed two high pressure liquid chromatography systems for the separation 
and purification of peptides. A stop flow spectrophotometer is available in the 
chemistry building if any rapid kinetic measurements are required. 
F. Collaborative Arrangements. The coagulation proteases used in this research 
will be prepared and purified in the laboratory of Earl Davie at the Univ. of 
Wash. (see attached letter). The majority of the kinetic studies will be carried 
out at Georgia Tech, although some studies may be done at the U. of Wash. At 




. We expect to receive Factor XII and kallikrein shortly. 
Cls has been supplied to us by Dr
a 
 . T. Y. Lin (Merck, Rahway, New Jersey). 
We also expect to study Cl; when he completes the purification of that complement 
protease. 
Principal Investigator Assurance  
The undersigned agrees to accept responsibility for the scientific and technical 
conduct of the research project and for provision of required progress reports if 
a grant is awarded as the result of this application. 
vv‘i,42: 	C 	‘)19.14-C-1,41-/ 
Jamhk C. Powers 
Principal Investigator 
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